伦敦的生物技术初创公司Baseimmune近日在A轮融资中成功募集了1130万美元（约900万英镑），这标志着其在利用人工智能技术设计和开发疫苗的道路上迈出了坚实的一步。本次融资活动得到了众多知名投资者的超额认购，其中包括MSD Global Health Innovation Fund、IQ Capital，以及早期投资者Hoxton Ventures、Creator Fund、Beast Ventures和Maki.vc。
Baseimmune公司致力于通过其先进的机器学习平台简化疫苗设计过程，这一平台有望革新传统的疫苗研发模式，提高效率并可能加速新疫苗的上市时间。此次募集的资金将主要用于进一步研发这一创新技术，同时推进相关疫苗项目的临床试验，以应对全球公共卫生领域的挑战。
投资者对Baseimmune的机器学习技术寄予厚望，认为其有潜力彻底改变生物医学界对疫苗开发的理解和实践。MSD Global Health Innovation Fund等投资者的参与，不仅为Baseimmune提供了必要的资金支持，也为其在全球医疗健康领域的合作打开了新的可能。
Baseimmune的A轮融资成功，不仅是对公司技术实力的认可，也是对人工智能在医疗健康领域应用前景的肯定。随着科技与医疗的深度融合，Baseimmune有望在疫苗研发这一关键领域取得突破，为全球公共卫生安全作出贡献。
英语如下：
**News Title:** “London Biotech Firm Baseimmune Raises $11.3M in Funding, AI Vaccine Design Platform Garners Attention”
**Keywords:** Baseimmune, Series A funding, machine learning vaccines
**News Content:** London-based biotech startup Baseimmune has recently secured $11.3 million (approximately £9 million) in its Series A funding round, marking a significant stride in its pursuit of using artificial intelligence for vaccine design and development. The oversubscribed round saw participation from prominent investors, including MSD Global Health Innovation Fund, IQ Capital, as well as early investors Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Baseimmune focuses on streamlining vaccine design through its advanced machine learning platform, which has the potential to revolutionize traditional vaccine development methods, enhancing efficiency and potentially accelerating the time to market for new vaccines. The funds raised will primarily be used to further develop this innovative technology and advance associated vaccine projects into clinical trials, addressing global public health challenges.
Investors are optimistic about Baseimmune’s machine learning capabilities, believing they could fundamentally alter the biomedical industry’s approach to vaccine development. The involvement of MSD Global Health Innovation Fund and others not only provides financial backing but also opens doors to potential collaborations within the global healthcare sector.
The successful Series A funding for Baseimmune not only validates the company’s technical prowess but also endorses the potential of AI in the healthcare domain. With the convergence of technology and medicine, Baseimmune is poised to make breakthroughs in vaccine research, contributing to global public health security.
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 1